These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38831049)

  • 21. Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review.
    Zhornitsky S; Oliva HNP; Jayne LA; Allsop ASA; Kaye AP; Potenza MN; Angarita GA
    Front Psychiatry; 2023; 14():1197890. PubMed ID: 37435405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The psychedelic renaissance: the next trip for psychiatry?
    Kelly JR; Baker A; Babiker M; Burke L; Brennan C; O'Keane V
    Ir J Psychol Med; 2022 Dec; 39(4):335-339. PubMed ID: 31543078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "We don't want to run before we walk": the attitudes of Australian stakeholders towards using psychedelics for mental health conditions.
    Kunstler BE; Smith L; Langmead CJ; Goodwin DM; Wright B; Hatty MA
    Public Health Res Pract; 2023 Sep; 33(3):. PubMed ID: 37699762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "How Do I Learn More About this?": Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics.
    Kruger DJ; Enghoff O; Herberholz M; Barron J; Boehnke KF
    J Psychoactive Drugs; 2023; 55(5):631-639. PubMed ID: 37078418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association between naturalistic use of psychedelics and co-occurring substance use disorders.
    Rabinowitz J; Lev-Ran S; Gross R
    Front Psychiatry; 2022; 13():1066369. PubMed ID: 36704738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of a new instrument for assessing attitudes on psychedelics in the general population.
    Žuljević MF; Buljan I; Leskur M; Kaliterna M; Hren D; Duplančić D
    Sci Rep; 2022 Oct; 12(1):18225. PubMed ID: 36309539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways.
    Sinha JK; Trisal A; Ghosh S; Gupta S; Singh KK; Han SS; Mahapatra M; Abomughaid MM; Abomughayedh AM; Almutary AG; Iqbal D; Bhaskar R; Mishra PC; Jha SK; Jha NK; Singh AK
    Ageing Res Rev; 2024 Apr; 96():102211. PubMed ID: 38307424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A survey of Australian psychiatrists' and psychiatry trainees' knowledge of and attitudes towards psychedelics in the treatment of psychiatric disorders.
    Grover C; Monds L; Montebello M
    Australas Psychiatry; 2023 Jun; 31(3):329-335. PubMed ID: 36753675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acid liberalism: Silicon Valley's enlightened technocrats, and the legalization of psychedelics.
    Tvorun-Dunn M
    Int J Drug Policy; 2022 Dec; 110():103890. PubMed ID: 36279734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Explaining trip generation during the COVID-19 pandemic: A psychological perspective.
    Mehdizadeh M; Fallah Zavareh M; Nordfjaern T
    J Transp Health; 2022 Sep; 26():101390. PubMed ID: 36091182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of real-time crash risk for expressway ramps using traffic, geometric, trip generation, and socio-demographic predictors.
    Wang L; Abdel-Aty M; Lee J; Shi Q
    Accid Anal Prev; 2019 Jan; 122():378-384. PubMed ID: 28689932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychedelics as Reemerging Treatments for Anxiety Disorders: Possibilities and Challenges in a Nascent Field.
    King F; Hammond R
    Focus (Am Psychiatr Publ); 2021 Jun; 19(2):190-196. PubMed ID: 34690582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities.
    Yaden DB; Johnson MW; Griffiths RR; Doss MK; Garcia-Romeu A; Nayak S; Gukasyan N; Mathur BN; Barrett FS
    Int J Neuropsychopharmacol; 2021 Aug; 24(8):615-623. PubMed ID: 33987652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M; Taylor RH; Tsapekos D; Young AH
    Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attitudes of European psychiatrists on psychedelics: a qualitative study.
    Žuljević MF; Breški N; Kaliterna M; Hren D
    Front Psychiatry; 2024; 15():1411234. PubMed ID: 38855648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis.
    Dourron HM; Strauss C; Hendricks PS
    Pharmacol Rev; 2022 Oct; 74(4):982-1027. PubMed ID: 36113878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ethical Issues Regarding Nonsubjective Psychedelics as Standard of Care.
    Yaden DB; Earp BD; Griffiths RR
    Camb Q Healthc Ethics; 2022 Oct; 31(4):464-471. PubMed ID: 36398520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Catalysts for change: the cellular neurobiology of psychedelics.
    Banks MI; Zahid Z; Jones NT; Sultan ZW; Wenthur CJ
    Mol Biol Cell; 2021 Jun; 32(12):1135-1144. PubMed ID: 34043427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aggressive behaviours associated with MDMA and psychedelics: a narrative review.
    Sayrafizadeh N; Ledwos N; Husain MI; Castle DJ
    Acta Neuropsychiatr; 2024 Feb; ():1-13. PubMed ID: 38329106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Animal Behavior in Psychedelic Research.
    Odland AU; Kristensen JL; Andreasen JT
    Pharmacol Rev; 2022 Oct; 74(4):1176-1205. PubMed ID: 36180111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.